Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Shuo Liu, Zhengming Jin, Depei Wu, MD PhD, Haiwen Huang, MD PhD

Blood (2019) 134 (Supplement_1): 3315.

https://doi.org/10.1182/blood-2019-125666

Published: 2019

Journal Articles

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Teresa Poggio, Linda Graessel, Stefanie Kreutmair, Cornelius Miething, Dietmar Pfeifer, Geoffroy Andrieux, Melanie Boerries, Marie Follo, Suzanne Turner, Robert Zeiser, MD, Justus Duyster, MD, Anna Lena Illert

Blood (2019) 134 (Supplement_1): 2542.

https://doi.org/10.1182/blood-2019-125589

Published: 2019

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Wenyu Shi, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 4069.

https://doi.org/10.1182/blood-2019-130063

Published: 2019

Journal Articles

Clinical Characteristic and Survival Outcome of Peripheral T Cell Lymphoma in a Chinese Population

Wenyu Li, MD PhD, Ling Huang, MD, Xinmiao Jiang, MD, Xiaojuan Wei, Hanguo Guo, Liu Sichu, MD, Chen Feili, MD, Zhanli Liang

Blood (2019) 134 (Supplement_1): 5271.

https://doi.org/10.1182/blood-2019-129552

Published: 2019

Journal Articles

TRAF1-ALK Fusion Predicts Poor Prognosis for ALK Positive Anaplastic Large Cell Lymphoma Patients with Chemotherapy and ALK Inhibitor

Ling Huang, MD, Xinmiao Jiang, MD, Hanguo Guo, Liu Sichu, MD, Xiaojuan Wei, Chen Feili, MD, Zhanli Liang, Wenyu Li, MD PhD

Blood (2019) 134 (Supplement_1): 5224.

https://doi.org/10.1182/blood-2019-126541

Published: 2019

Journal Articles

Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma

Elif Atabay, PhD, Qi Wang, PhD, Ambrogio Chiara, PhD, Taek-Chin Cheong, PhD, Silvia Peola, Geeta G Sharma, PhD, Luca Mologni, PhD, Carlo Gambacorti-Passerini, MD, Claudia Voena, PhD, Roberto Chiarle, MD

Blood (2019) 134 (Supplement_1): 5060.

https://doi.org/10.1182/blood-2019-132188

Published: 2019

Journal Articles

Brefeldin Α Reduces STAT3 Dependent Survival of Acute Leukemia and Neuroblastoma Cells

Mitsuteru Hiwatari, MD PhD, Kentaro Watanabe, MD, Yasuo Kubota, MD, Masahiro Sekiguchi, MD, Junko Takita, MD PhD

Blood (2019) 134 (Supplement_1): 5762.

https://doi.org/10.1182/blood-2019-130056

Published: 2019

Journal Articles

NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation

Elias Drakos, MD PhD Prof., Konstantina Stathopoulou, MSc., Lingxiao Li, PhD, Daniel Bilbao, Vasiliki Leventaki, Pedro Farrajota Neves Da Silva, MD, Vasileios Atsaves, PhD, Anders Österborg, MD PhD, L. Jeffrey Medeiros, MD, Francisco Vega, MD PhD, Jonathan H. Schatz, MD, Francois Claret, PhD, George Z. Rassidakis, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 2796.

https://doi.org/10.1182/blood-2019-130457

Published: 2019

Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao

Blood (2019) 134 (Supplement_1): 1556.

https://doi.org/10.1182/blood-2019-122369

Published: 2019

Journal Articles

Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL

Rui Wu, MD PhD, Elena Ivan, MD, Anagh Anant Sahasrabuddhe, PhDMSc,BSc, Timothy Shaw, PhD, Charles G. Mullighan, MBBS, MD, Vasiliki Leventaki, Kojo S. J. Elenitoba-Johnson, MD, Megan S. Lim, MD PhD

Blood (2019) 134 (Supplement_1): 1510.

https://doi.org/10.1182/blood-2019-127453

Published: 2019

Journal Articles

The DNA Helicase Hells Is a New Unconventional Player in ALK - Anaplastic Large Cell Lymphoma Biology

Valentina Fragliasso, PhD, Annalisa Tameni, Akanksha Verma, Rohan Bareja, Tayla Heavican, Javeed Iqbal, PhD, Gloria Manzotti, PhD, Danilo Fiore, PhD, Valentina Mularoni, PhD, Wing C. Chan, MD, Francesco Merli, MD, Olivier Elemento, PhD, Alessia Ciarrocchi, PhD, Giorgio Inghirami, MD

Blood (2019) 134 (Supplement_1): 1477.

https://doi.org/10.1182/blood-2019-122701

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

FOXM1 and the NPM-ALK/STAT3 Axis Form a Novel Positive Feedback Loop in Promoting the Oncogenesis of ALK-Positive Anaplastic Large Cell Lymphoma

Peng Wang, MD PhD, Moinul Haque, Jing Li, Yung-Hsing Huang, Meaad Almowaled, Carter Bargar, Adam Karpf, Will Chen, Suzanne Turner, Raymond Lai, PhD MD

Blood (2018) 132 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2018-99-115743

Published: 2018

Journal Articles

CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients

Soumya Sundara Rajan, MSc, Lingxiao Li, PhD, Kranthi Kunkalla, Amit Dipak Amin, PhD, Nitin Agarwal, Francisco Vega, MD PhD, Jonathan H. Schatz, MD

Blood (2018) 132 (Supplement 1): 779.

https://doi.org/10.1182/blood-2018-99-114692

Published: 2018

Journal Articles

Towards Improved Models of NPM-ALK Induced T-Cell Lymphoma

Sophia Ehrenfeld, MSc, Khalid Shoumariyeh, Teresa Poggio, Robin Khan, Desiree Melanie Redhaber, Stefanie Kreutmair, MD, Cathrin Klingeberg, Anna Lena Illert, MD, Justus Duyster, Prof., Cornelius Miething, MD

Blood (2018) 132 (Supplement 1): 1342.

https://doi.org/10.1182/blood-2018-99-115872

Published: 2018

Journal Articles

Identification of Novel Pathways and Small Molecules Able to Down Regulate Oncogenes Expression By Compounds Screening Approaches in Acute Leukemia and Neuroblastoma Cells

Mitsuteru Hiwatari, MD PhD, Kentaro Watanabe, MD, Yasuo Kubota, MD, Shunsuke Kimura, MD, Junko Takita, MD, PhD

Blood (2018) 132 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2018-99-111090

Published: 2018

Journal Articles

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Masahiro Sekimizu, MD PhD, Reiji Fukano, MD PhD, Ilseung Choi, MD PhD, Akiko Kada, PhD, Akiko Saito, MD, Ryuta Asada, PhD, Tetsuya Mori, MD PhD, Hirokazu Nagai, MD PhD

Blood (2018) 132 (Supplement 1): 2924.

https://doi.org/10.1182/blood-2018-99-112708

Published: 2018

Journal Articles

NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Mediated By STAT1 Antagonism of STAT3 Survival Signaling, Revealing a Novel Therapeutic Strategy

Soumya Sundara Rajan, M.Sc, Amit Dipak Amin, PhD, Lingxiao Li, PhD, Delphine C. M. Rolland, PharmD, PhD, Haiquan Li, PhD, Soham Puvvada, MD, Yves Lussier, MD, Megan S. Lim, MDPhD, Jonathan H. Schatz, MD

Blood (2017) 130 (Supplement 1): 2506.

https://doi.org/10.1182/blood.V130.Suppl_1.2506.2506

Published: 2017

NARROW

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Clinical Characteristic and Survival Outcome of Peripheral T Cell Lymphoma in a Chinese Population

TRAF1-ALK Fusion Predicts Poor Prognosis for ALK Positive Anaplastic Large Cell Lymphoma Patients with Chemotherapy and ALK Inhibitor

Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma

Brefeldin Α Reduces STAT3 Dependent Survival of Acute Leukemia and Neuroblastoma Cells

NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL

The DNA Helicase Hells Is a New Unconventional Player in ALK - Anaplastic Large Cell Lymphoma Biology

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

FOXM1 and the NPM-ALK/STAT3 Axis Form a Novel Positive Feedback Loop in Promoting the Oncogenesis of ALK-Positive Anaplastic Large Cell Lymphoma

CRISPR/Cas9 Generation of Npm1-Alk in Transplantable Murine Hematopoietic Stem Cells Accurately Models ALK-Positive Lymphoma in Recipients

Towards Improved Models of NPM-ALK Induced T-Cell Lymphoma

Identification of Novel Pathways and Small Molecules Able to Down Regulate Oncogenes Expression By Compounds Screening Approaches in Acute Leukemia and Neuroblastoma Cells

Phase II Trial of CH5424802 (alectinib hydrochloride) for Recurrent or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

NPM1-ALK Overexpression-Driven Toxicity in ALCL Is Partner Dependent and Mediated By STAT1 Antagonism of STAT3 Survival Signaling, Revealing a Novel Therapeutic Strategy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only